Alkermes Plc
Veridion Score
Composite trend over time
Why is ALKS moving today?
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for ALKS.
ALKS insider activity
Alkermes Plc
2 insiders bought in the last 90 days
Net selling: -$8.4M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-04 | 2026-06-04 | Gaffin David Joseph | Insider | sell | $43.05 | 2,034 | 229,524 | $88K | SEC Form 4 |
| 2026-06-01 | 2026-06-01 | Hopkinson Craig C. | Insider | sell | $41.67 | 9,000 | 77,389 | $375K | SEC Form 4 |
| 2026-06-01 | 2026-06-01 | Hopkinson Craig C. | Insider | buy | $19.34 | 5,000 | 86,389 | $97K | SEC Form 4 |
| 2026-05-29 | 2026-05-29 | Parisi Samuel Joseph | Insider | sell | $42.36 | 16,217 | 7,717 | $687K | SEC Form 4 |
| 2026-05-29 | 2026-05-29 | Parisi Samuel Joseph | Insider | buy | $19.34 | 12,825 | 23,934 | $248K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 64 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moALKS contract awards, year to date.
Public federal awards linked to this ticker.
ALKS lobbying filings, year to date.
Registered lobbying filings matched to Alkermes Plc.